Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial

Akihiro Ohba,Hideki Ueno,Satoshi Shiba,Naohiro Okano,Takaaki Kobayashi,Fumio Nagashima,Naoki Sasahira,Mitsuhito Sasaki,Hiroshi Imaoka,Yasunari Sakamoto,Shunsuke Kondo,Chigusa Morizane,Masato Ozaka,Masafumi Ikeda,Junji Furuse,Takuji Okusaka

European Journal of Cancer（2022）

引用 2|浏览18

暂无评分

摘要

•Phase 1b trial of S-1, irinotecan, and oxaliplatin in pancreatic cancer.•The RD was S-1 80 mg/m2, irinotecan 150 mg/m2, and oxaliplatin 85 mg/m2.•The ORR was 51.1%, and PFS and OS were better than those of the historical FOLFIRINOX.

查看译文

关键词

Pancreatic cancer,S-1,Irinotecan,Oxaliplatin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要